M4 Receptor Activators Treat Alzheimer's Parkinson's Schizophrenia
Summary
The USPTO published patent application US20260098026A1 for M4 receptor activator/modulator compounds of Formula I, filed September 15, 2023. The compounds are intended for treating M4-mediated neurological disorders including Alzheimer's Disease, Parkinson's Disease, schizophrenia, pain, addiction, and sleep disorders. The application covers the compounds, N-oxides, salts, preparation processes, intermediates, and pharmaceutical compositions.
What changed
The USPTO published a patent application for M4 receptor activator/modulator compounds of Formula I, covering their pharmaceutical compositions and uses in treating neurological and psychiatric disorders. The application claims priority to an earlier filing and includes detailed chemical structures, synthetic processes, and therapeutic applications.
Pharmaceutical companies developing CNS therapeutics should monitor this application for potential freedom-to-operate considerations. The broad claim scope covering multiple neurological indications may affect patent strategy for competing M4-targeted therapies. Legal professionals should advise on patent prosecution developments and potential licensing opportunities.
What to do next
- Monitor for patent prosecution updates
- Evaluate licensing opportunities for M4 therapeutic applications
- Review compound claims for freedom-to-operate analysis
Archived snapshot
Apr 9, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
M4 ACTIVATORS/MODULATORS AND USES THEREOF
Application US20260098026A1 Kind: A1 Apr 09, 2026
Inventors
Hanh Nguyen, Shea Johnson, Xiaofeng Zhang, Sokhom Pin, Jongwon Lim, Hongjun Zhang
Abstract
The present disclosure provides compounds of Formula I: (I), or an N-oxide thereof, or a pharmaceutically acceptable salt of the compound or the N-oxide, wherein: A, Y, m, n, p, R1, R2, R3, R3a, R4, R5, R6, R7, and Z are as described herein; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, N-oxides, or salts, and their uses for treating M4-mediated (or M4-associated) disorders including, e.g., Alzheimer's Disease, Parkinson's Disease, schizophrenia (e.g., its cognitive and negative symptoms), pain, addiction, and a sleep disorder.
CPC Classifications
C07D 401/14 A61K 31/4545 A61K 31/496 A61K 31/497 A61K 31/4995 A61K 31/501 A61K 31/506 A61K 31/513 A61K 31/519 A61K 31/5365 A61K 31/5377 A61K 31/538 A61K 31/695 C07B 59/002 C07D 405/14 C07D 409/14 C07D 413/14 C07D 417/14 C07D 471/04 C07D 487/04 C07D 487/08 C07D 491/107 C07D 495/10 C07D 498/04 C07F 7/0812 C07B 2200/05
Filing Date
2023-09-15
Application No.
19112200
Related changes
Get daily alerts for USPTO Patent Applications - Organic Chemistry (C07D)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Organic Chemistry (C07D) publishes new changes.